Literature DB >> 2012515

Pneumocystis carinii pneumonia in patients with primary brain tumors.

J W Henson1, J K Jalaj, R W Walker, D E Stover, A O Fels.   

Abstract

All histologically documented episodes of Pneumocystis carinii pneumonia in adult patients with primary brain tumors treated at Memorial Sloan-Kettering Cancer Center, New York, NY, since 1981, were retrospectively reviewed. Pneumocystis carinii pneumonia was histologically documented 11 times in 10 patients. During the same 8-year interval, approximately 587 adults were seen at the center for a brain tumor, 90% of whom received ongoing therapy. Therefore, in at least 1.7% (10/587) of our patients with brain tumors, P carinii pneumonia developed. The median duration of dexamethasone therapy at the onset of P carinii pneumonia symptoms was 2.75 months. Symptoms began during tapering of steroid therapy in eight episodes. Bronchoscopy was diagnostic in the eight cases in which it was performed. Four episodes (40%) were fatal. Trimethoprim-sulfamethoxazole prophylaxis may be indicated in some patients with brain tumors, especially during tapering of steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012515     DOI: 10.1001/archneur.1991.00530160074017

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  Lymphocyte surge as a marker for immunorestitution disease due to Pneumocystis jiroveci pneumonia in HIV-negative immunosuppressed hosts.

Authors:  V C C Cheng; I F N Hung; A K L Wu; B S F Tang; C M Chu; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-13       Impact factor: 3.267

2.  Infections in neuro-oncology.

Authors:  P Gaviani; A Silvani; E Lamperti; A Botturi; G Simonetti; I Milanesi; D Ferrari; A Salmaggi
Journal:  Neurol Sci       Date:  2011-11       Impact factor: 3.307

3.  Corticosteroid use in neuro-oncology: an update.

Authors:  Patrick Roth; Caroline Happold; Michael Weller
Journal:  Neurooncol Pract       Date:  2014-10-09

Review 4.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

Review 5.  Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors.

Authors:  Jeffrey J Raizer; Karan S Dixit
Journal:  Curr Treat Options Oncol       Date:  2015-08

Review 6.  Corticosteroids in brain cancer patients: benefits and pitfalls.

Authors:  Jörg Dietrich; Krithika Rao; Sandra Pastorino; Santosh Kesari
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

Review 7.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study.

Authors:  N A Maskell; D J Waine; A Lindley; J C T Pepperell; A E Wakefield; R F Miller; R J O Davies
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

9.  Genotypic variation in Pneumocystis jirovecii isolates in Britain.

Authors:  R F Miller; A R Lindley; A Copas; H E Ambrose; R J O Davies; A E Wakefield
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

10.  Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features.

Authors:  D Schiff
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.